Astex Announces Early Transfer of Epigenetics Project to GSK

17-Jan-2012 - Astex Pharmaceuticals, Inc. announced that the multi-year collaboration to discover cancer therapeutics based on epigenetic targets entered into by SuperGen, Inc. and GlaxoSmithKline (GSK) in November 2009 is terminating and existing research work and assets generated under the CLIMB™ epigenetic ...

Astex Achieves Milestones in GSK Collaboration

04-May-2011 - Astex Therapeutics announced that it has achieved multiple early milestones in its fragment-based drug discovery collaboration with GlaxoSmithKline which commenced in November 2009. Total milestone payments received under the collaboration have now reached £5.9 million. The milestones relate to ...

Astex Announces Commencement of Phase I Study for AZD5363 in Anti-Cancer Collaboration with AstraZeneca

14-Apr-2011 - Astex Therapeutics confirmed the commencement of a Phase I study for AZD5363, a Protein Kinase B (PKB, also known as Akt) inhibitor. AZD5363 is a clinical candidate selected in January 2010 by AstraZeneca subsequent to its collaborative programme with Astex. The collaborative programme ...

Supergen and Astex Therapeutics enter definitive merger agreement

08-Apr-2011 - SuperGen, Inc. and Astex Therapeutics Limited jointly announced that they have entered into a definitive agreement to merge the two companies, subject to customary closing conditions, including regulatory and shareholder approvals.The combined entity, to be named Astex Pharmaceuticals, Inc., is ...

GENEART wins "European Biotechnica Award"

The British company Astex Therapeutics Limited and the German company immatics biotechnologies GmbH were honoured as finalists

09-Oct-2008 - GENEART AG, a leader in gene synthesis and specialist in the field of Synthetic Biology was awarded the "European Biotechnica Award" during the ceremonial opening of "Biotechnica 2008". The prize was presented by the Vice President of the European Commission, Günter Verheugen. The award comprises ...

Astex Announces New Drug Discovery Alliance with Janssen Pharmaceutica N.V.

11-Jun-2008 - Astex Therapeutics Limited announced that Astex and Janssen Pharmaceutica have entered into a research alliance focused on the research, development and commercialisation of novel drugs for the treatment of cancer. The new agreement grants Janssen Pharmaceutica a worldwide exclusive license to ...

Astex Grants Cytochrome P450 License to GlaxoSmithKline

26-Apr-2007 - Astex Therapeutics announced that it has granted a non-exclusive, worldwide license to its cytochrome P450 intellectual property to GlaxoSmithKline. Under the terms of the agreement, GlaxoSmithKline will pay an up-front fee to Astex in return for a license under Astex's portfolio of granted and ...

Astex announces IND approval for novel cancer drug AT7519

28-Jun-2005 - Astex announced that the United States Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for the clinical development of its proprietary cell cycle inhibitor, AT7519, for the treatment of cancer. AT7519 was discovered and developed internally using ...

Astex announces Clinical Trial Authorization for novel cancer drug AT7519 and plans for two further new drug filings

26-May-2005 - Astex announced that the UK Medicines and Healthcare Products Regulatory Agency (MHRA) has approved its Clinical Trial Authorisation (CTA) application for the clinical development of its proprietary cell cycle inhibitor, AT7519, for the treatment of cancer. The Company now plans to initiate a ...

Astex announces Clinical Trial Authorization for novel cancer drug AT7519 and plans for two further new drug filings

24-May-2005 - Astex announced that the UK Medicines and Healthcare Products Regulatory Agency (MHRA) has approved its Clinical Trial Authorisation (CTA) application for the clinical development of its proprietary cell cycle inhibitor, AT7519, for the treatment of cancer. The Company now plans to initiate a ...